January 23, 2024

Press Release
Mitsubishi Tanabe Pharma Corporation
Pfizer Japan Inc.
The Research Foundation for Microbial Diseases of Osaka University

Co-promotion of“GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria,Tetanus, Inactivated Polio and Hib Combined Vaccine

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka;
Representative Director: Akihiro Tsujimura; hereafter, "MTPC") and Pfizer
Japan Inc. (Head Office: Shibuya-ku, Tokyo; President: Akihisa Harada,
hereafter "Pfizer") will conduct co-promotion activities in Japan for "GOBIK
Aqueous Suspension Injection Syringes" (hereafter "GOBIK"), Adsorbed
Diphtheria-Purified Pertussis-Tetanus-Inactivated Polio-Haemophilus type b
conjugate Combined Vaccine , for which the Research Foundation for Microbial
Diseases of Osaka University (Headquarters: Suita -city, Osaka; DirectorGeneral: Yoshihiro Yoneda; hereafter, "BIKEN") has been obtained themarketing approval. GOBIK will be manufactured by BIKEN, distributed by
MTPC and jointly promoted by MTPC and Pfizer.
GOBIK is a vaccine that combined the antigenic components of TETRABIK(adsorbed diphtheria-purified pertussis-tetanus-inactivated polio [Sabin strain]
combined vaccine) with those of Haemophilus influenzae type b（Hib）. GOBIK
is a vaccine jointly developed by BIKEN and MTPC, and was first approvedin Japan as the combination vaccine for five diseases on March 27, 2023. The
combination vaccine for five diseases has been selected as one of the vaccines withhigh development priority according to the “Basic plan about vaccination” stipulated
in 2014. At present, the total number of shots of routine vaccinations required by
two years old is twenty or more, and combination vaccines will reduce the numberof shots and the burden on infants and guardians.

1Routine vaccinations with the combination vaccine for five diseases isplanned to begin in April 2024, and preparations are underway for the launch ofGOBIK in March 2024. MTPC, Pfizer and BIKEN will continue to contribute to publichealth in Japan through the manufacture, stable supply and promotion of GOBIK.
◆Contact information
Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group,
Corporate

Communications

Div.,

Osaka

Corporate

Communications

Dept.)

TEL: 06-6205-5119
Public Relations Section, The Research Foundation for Microbial Diseases ofOsaka UniversityTEL: 06-6877-4802◆Please refer to the following URL for the infections to be prevented with pertussis,
diphtheria, tetanus, inactivated polio and Hib combined vaccine.
https://www.cdc.gov/vaccines/parents/diseases/index.html◆About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi
Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world,
founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquarteredin Dosho-machi, Osaka, the birthplace of Japan’s pharmaceutical industry. MCG haspositioned health care as its strategic focus in its management policy, “Forging thefuture”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end,
MTPC is working on the disease areas of central nervous system, immunoinflammation, diabetes and kidney, and cancer. MTPC is focusing on “precisionmedicine” to provide drugs with high treatment satisfaction by identifying patient
populations with high potential for efficacy and safety. In addition, MTPC is working
to develop “around the pill solutions” to address specific patient concerns based ontherapeutic medicine, including prevention of diseases, pre-symptomatic diseasecare, prevention of aggravation and prognosis. For more information, go tohttps://www.mt-pharma.co.jp/e/◆About Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people
that extend and significantly improve their lives. We strive to set the standard for
quality, safety, and value in the discovery, development, and manufacture of health2care products, including innovative medicines and vaccines. Every day, Pfizer
colleagues work across developed and emerging markets to advance wellness,prevention, treatments, and cures that challenge the most feared diseases of ourtime. Consistent with our responsibility as one of the world's premier innovative
biopharmaceuticalcompanies,

wecollaborate

withhealthcareproviders,

governments, and local communities to support and expand access to reliable,
affordable health care around the world. For more than 170 years, Pfizer has worked
to make a difference for all who rely on us. For more information, go towww.pfizer.com (Pfizer Inc.), www.pfizer.co.jp、Instagram、X（Pfizer Japan Inc.）◆About Research Foundation for Microbial Diseases of Osaka University
The BIKEN is a Specialty Bio-Pharmaceutical Organization engaged in the Research,
Development and Supply of Vaccines. Since its establishment in 1934, BIKEN hascontributed to public health by developing, manufacturing and supplying a numberof first vaccines made in Japan and providing advanced laboratory test services.
Based on its mission "Protect the precious lives of people around the world throughexcellent vaccines." the BIKEN will continue to pursue the advancement of advanced
science and unique biotechnology toward a healthy society free from disease anxiety.
https://www.biken.or.jp/english

3